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Introduction

Significance of the project:
Anti-erbB2 (Herceptin) and doxorubicin are effective treatments for breast cancers that over-express the Her2/neu oncogene. In pivotal trials that lead to its approval, anti-erbB2 administered in combination with other agents, particularly doxorubicin, 29% of patients developed cardiac dysfunction, and in some cases fatal, cardiomyopathy [1] [2] [3] 10] . The mechanism of this synergistic toxicity induced by anti-erb2 is not understood. To address this problem, we have developed novel in vitro and in vivo rat animal models that exhibit cardiac toxicity synergism with doxorubicin and anti-rat erbB2 compared to either treatment alone. We utilize an anti-rat-erbB2 monoclonal antibody (clone 7.16.4) that shows the same biological effects in rat cells expressing erbB2, as Herceptin does in human breast cancer cells, including similar epitope recognition, inhibition of cell growth, reversion of phenotype and reduction in cancer cell growth in vivo [4] . In this model, Akt, a well-known anti-apoptotic pathway protein in the heart, linked to the erbB2, is inactivated. This finding of Akt inactivation is consistent with Herceptin's mechanism of action in breast cancer cells [5, 6] . Cardiotrophin-1 and urocortin both stimulate the Akt pathway through different receptors expressed in the heart [7] [8] [9] , and not breast cells; thus, treatment with these peptides, may circumvent the erbB-linked Akt pathway and provide protection during doxorubicin or doxorubicin/anti-erbB2 treatment. The hypothesis of this proposal is that activation of Akt in the heart through heart specific receptors, during doxorubicin and anti-erbB2 therapy, will protect from cardiac toxicity and not diminish doxorubicin and antierbB2 tumor cell killing in breast cancer cells. Specific Aim 1 Determine the role of Akt activation, by non-erbB2 pathways, in protection of cardiomyocytes against toxicity induced by anti-erbB2, doxorubicin, chemical inhibitors of erbB1 or erbB2 or combination treatments.
Specific Aim 2 Screen a panel of commonly used human breast cancer cell lines, breast cancer tissue arrays and normal epithelium arrays for expression to urocortin or cardiotrophin-1 peptides or their receptors.
Specific Aim 3
Determine whether activation of Akt, by the non-erbB2 pathways, (urocortin or cardiotropin-1), will preferentially protect cardiomyocytes and not breast cancer cells, against toxicity induced by anti-erbB2, doxorubicin, inhibitors of erbB1 or erbB2 or combined treatments.
Specific Aim 4
Determine whether in vivo pretreatment with Akt-inducing urocortin or cardiotropin-1 provides protection for doxorubicin and /or anti-erbB2 treatment induced cardiac toxicity in rats without affecting anti-neoplastic effects of therapy. Body: Research Accomplishments To test our hypothesis, our specific aims are: Specific Aim 1 Determine the role of Akt activation, by non-erbB2 pathways, in protection of cardiomyocytes against toxicity induced by anti-erbB2, doxorubicin, chemical inhibitors of erbB1 or erbB2 or combination treatments.
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Active-MAPK p-AKT β-Actin Specific Aim 3 Determine whether activation of Akt, by the non-erbB2 pathways, (urocortin or cardiotropin-1), will preferentially protect cardiomyocytes and not breast cancer cells, against toxicity induced by anti-erbB2, doxorubicin, inhibitors of erbB1 or erbB2 or combined treatments.
Above Left figure: The number of metabolically active neonatal rat cardiomyocytes was determined by the MTT assay. Neonatal rat cardiomyocytes were treated doxorubicin and urocortin. Urocortin protects neonatal rat cardiomyocytes from cardiac toxicity. (n=36) Figure ( left) The number of metabolically active MCF10A cells was determined by the MTT assay. MCF10A cells were treated Doxorubicin (0.05uM) and Urocortin (variable concentrations). Urocortin does not protect MCF10A cells from doxorubicin toxicity. (n=12) This suggests that stimulation of other Akt pathways, may be protective with dual doxorubicin and anti-erbB2 treatment in the heart but not in breast cells that have a receptor. Future studies will test if urocortin can offer protection in this combined treatment in cardiomyocytes.
The following is validation of two cytotoxicity assays with doxorubicin which will apply to Aim 1 and 3: Using this same model, but using only 3 tail vein intravenous injections of 9 mg/kg doxorubicin given every 2 weeks, we applied the concept in Specific Aim 4 by inhibiting erbB1 and erbB2. Giving a combined treatment of Doxorubcin and AG825, an erbB2 inhibitor, synergistic toxicity was observed resulting in a marked reduction in the cardiac fractional shortening evaluated by in vivo transthoracic echocardiography. This model will be evaluated for protection with urocortin, an pAKT inducer along side the rat model.
Monoclonal antibody production:
We require a large amount of antibody to perform the anti-erbB2 in vitro and in vivo experiments. We had a three month period when we could not make antibody because of a technical problem that was finally solved. This had an impact on rat studies, although the mouse model listed above may be added if we can not make enough antibody for these complete studies. I will see what can be accomplished this year before changing the protocol. The hybridoma we use to produce 7.16.4 has always been grown in an Integra flask (Integra Biosciences). We have two flasks going at a time to make about 5mg/week. In order to meet the large quantity of antibody we need for these animal studies, we also set up a Hollow fiber system HFS (Bellco) to increase antibody production. Our antibody is routinely checked for activity by flow cytometry and western blotting (erbB2 phosphoryation). Each rat in a study requires 4mg/study. We were unsuccessful in adapting our hybridoma to the HFS, even with close consultation with the company's president. Some hybridomas are not adaptable to the HFS.
Key Research Accomplishments
• Akt expressing Adenovirus protects against doxorubicin toxicity in cardiomyocytes Doxorubicin administered to rats induces a dose-dependent cardiomyopathy creating a useful invivo model for investigation of cardiotoxicity. Both doxorubicin administration and presence of indwelling venous catheters have been associated with thrombus formation. The study aim was to determine feasibility of drug delivery and degree of thrombogenesis related to long-term indwelling catheter use in a cardiotoxicity model. Rats receiving doxorubicin or saline via jugular catheters coated with end-point immobilized heparin were compared to rats receiving similar treatments via direct jugular intravenous injection (venotomy). Onset of cardiotoxicity, defined by reduction in fractional shortening to or below 45%, was determined by echocardiography. Thrombogenesis was assessed by observation of atrial thrombi and pulmonary emboli as determined by post-mortem and histologic examination. A significantly greater proportion of the doxorubicin treated/catheterized group (87.5%) achieved cardiotoxicity relative to the doxorubicin treated/venotomy group (28.6%). This was reflected by an earlier and more precipitous decline in fractional shortening demonstrated by the doxorubicin treated/catheterized rats. Despite this, rats from catheterized groups demonstrated improved weight maintenance relative to venotomy groups. Although significant differences in presence of pulmonary emboli between groups were not observed, 50% of the doxorubicin treated/catheterized group developed vegetative endocarditis. Although development of such lesions represents alteration of the model-induced cardiac disease, we submit that the more reliable and early induction of desired endpoint, in addition to improved weight maintenance, represent model refinements. Development of valvular vegetations is similar to complications observed in cancer patients such that this model may serve as a means to study formation and prevention of such lesions.
This study determined that we could use the catheterized rat for this model. Using this system will allow a central line in the rat that can be used to deliver inhibitors of erbB2 pathway (antibody and small molecule inhibitors) as well as withdraw blood that can be tested for cardiac biomarkers of damage. The below tables and figures are part of a manuscript in press. Part II: Summary Cardiac toxicity is a major drawback to doxorubicin as a cancer-treating drug. Moreover, anti-erbB2 antibody therapy (i.e., trastuzumab) for breast cancer treatment potentiates the effects of doxorubicin on the heart, resulting in even more frequent and severe cardiac toxicity. To understand the mechanism of doxorubicin cardiac toxicity and the synergy of this drug with trastuzumab, we developed an in vivo rat model that exhibits progressive loss of cardiac function with doxorubicin treatment. By ten weeks of doxorubicin treatment, rats treated with (2.5 mg/kg dose) doxorubicin (every week for six weeks, frequency) develop a significant reduction in fractional shortening, 39.1% versus 71.1% in saline controls as measured by echocardiography. Immunoblot analysis of cardiac tissue obtained from rats manifesting doxorubicin toxicity showed that this loss of cardiac function is accompanied by a parallel increase in levels of both the erbB2 protein and the major erbB2 ligand, NRG1β. Furthermore, significant ly increased levels of the activated (i.e., phosphorylated) forms of AKT, mTOR, p70S6 kinase, and GSK3 β are also seen in these doxorubicin-injured hearts, consistent with activation of downstream signaling by the erbB2 receptor during response of the heart to doxorubicin. These elevations of erbB2 protein are not accompanied by elevations in erbB2 mRNA levels, however, suggesting post-transcriptional mechanisms for elevation of erbB2 levels in doxorubicin-injured heart tissue. We therefore considered the potential role of Hsp90, a prototypical cardiac stress response protein, as a stabilizing carrier of erbB2 in the setting of doxorubicin toxicity. Consistent with our expectations, we found significantly increased levels of Hsp90, as well as evidence of Hsp90/ erbB2 binding (by coprecipitation), suggesting that the Hsp90 stress response stabilizes erbB2 and subsequently leads to a cytoprotective response through the AKT signaling pathway. Thus, our results provide a plausible mechanism for the marked susceptibility of the heart to anti-erbB2 therapy in the setting of concomitant doxorubicin therapy. 
